Organogenesis (ORGO) Set to Announce Quarterly Earnings on Thursday

Organogenesis (NASDAQ:ORGO) is scheduled to post its quarterly earnings results after the market closes on Thursday, May 9th. Analysts expect Organogenesis to post earnings of ($0.03) per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Organogenesis Stock Performance

Organogenesis stock opened at $2.39 on Tuesday. The firm has a fifty day simple moving average of $2.82 and a two-hundred day simple moving average of $3.09. Organogenesis has a twelve month low of $1.96 and a twelve month high of $4.70. The company has a market capitalization of $315.38 million, a PE ratio of 59.76 and a beta of 1.60. The company has a quick ratio of 2.44, a current ratio of 2.80 and a debt-to-equity ratio of 0.22.

Analyst Ratings Changes

Separately, Cantor Fitzgerald restated an “overweight” rating and set a $5.00 target price on shares of Organogenesis in a report on Friday, March 1st.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.